2023 World Conference on Lung Cancer (Posters)-EP08.02. Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC?

EP08.02. Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC? - PDF(Slides)

Back to course

Pdf Summary

The study aimed to determine the proportion of patients with stage III non-small cell lung cancer (NSCLC) who completed their prescribed course of chemoradiotherapy (CRT) and would be eligible for adjuvant durvalumab, an immunotherapy treatment. A prospective database was analyzed for patients who received platinum-based CRT for stage III NSCLC. Early treatment cessation (ETC) was defined as not receiving the complete prescribed radiation dose. Logistic regression was used to identify potential factors associated with ETC. <br /><br />Out of 265 patients, only 20 (3.9%) had early treatment cessation, while 245 (96.1%) completed their full course of radiotherapy. Reasons for early cessation included sepsis, thromboembolism, and esophagitis. No variables were found to be significantly associated with ETC. ETC occurred in 2.5% of patients with ECOG 0, 9.6% with ECOG 1, and 8% with ECOG 2, but this difference was not statistically significant. ETC rates were also similar between patients aged over 70 and those under 70. <br /><br />The findings of the study are reassuring, indicating that 96% of patients in a comprehensive cancer center were able to complete their concurrent CRT. These results suggest that the majority of appropriately selected and managed patients with stage III NSCLC can tolerate CRT, making them eligible for adjuvant durvalumab. The study emphasizes the importance of completing the prescribed course of CRT to ensure access to the benefits of adjuvant immunotherapy.

Asset Subtitle

Michael MacManus

Meta Tag

Speaker Michael MacManus

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

proportion of patients

stage III non-small cell lung cancer

NSCLC

completed

prescribed course

chemoradiotherapy

eligible

adjuvant durvalumab

immunotherapy treatment

early treatment cessation